Kuroda Junya
Nihon Rinsho. 2015 Jan;73(1):119-23.
Multiple myeloma (MM) remains mostly incurable despite the recent progress in the treatment strategy. One of novel fields for anti-MM therapeutic strategy is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38. Both antigens are highly expressed in more than 90% of MM patients, and the clinical trials have shown promising anti-MM effects, especially in combination with immunomodulatory agent lenalidomide. We also discuss the characteristics and the results of clinical trials of other MoAbs, such as tabalumab against B cell activating factor or dacetuzumab against CD40, being developed for MM.
尽管治疗策略最近取得了进展，但多发性骨髓瘤（MM）大多仍无法治愈。抗MM治疗策略的一个新领域是开发针对骨髓瘤特异性抗原的单克隆抗体（MoAbs）免疫疗法。本文重点关注几种用于MM的新兴且有前景的新型MoAbs的基础和临床方面，例如靶向CS1的埃罗妥珠单抗和靶向CD38的达雷妥尤单抗。这两种抗原在超过90%的MM患者中高表达，并且临床试验已显示出有前景的抗MM效果，特别是与免疫调节剂来那度胺联合使用时。我们还讨论了正在为MM开发的其他MoAbs的特性和临床试验结果，例如针对B细胞活化因子的塔巴珠单抗或针对CD40的达西珠单抗。
